Nixon Lab Findings Presented at AAIC 2017 Scientific Meeting in London, UK

New York – Ralph Nixon, MD, PhD, Director of the Center for Dementia Research, reported his latest findings in a Developing Topics poster titled, “Antagonism of p38 MAPK Alpha (p38α) Reverses APP-Induced Endosomal Abnormalities and Improves Lysosomal Dysfunction in Down Syndrome Fibroblasts.”          The poster presentation at the Alzheimer’s Association International Conference in London, England, was the result of Dr. Nixon’s work, in collaboration with EIP Pharma. The investigators found that the EIP licensed investigational drug Neflamapimod reversed a critical Alzheimer’s related physiologic defect in human patient cells cultured from individuals with a genetic defect predisposing them to early onset Alzheimer’s disease. Dr. Nixon recently published a review in the FABSEB Journal on a key underlying dysfunction in Alzheimer’s disease.